Promising Drug for Treatment of Severe Lung Inflammation in COVID-19 Patients: Yeshiva University
May 23, 2020
May 23, 2020
BRONX, New York, May 23 -- Yeshiva University's Albert Einstein College of Medicine issued the following news release:
Montefiore Health System and Albert Einstein College of Medicine are the first sites in the nation to begin evaluating an investigational drug in two separate, FDA-approved trials: one to treat mild-to-moderate cases of COVID-19 and the other to treat severely ill COVID-19 patients. They are hopeful that the drug, leronlimab, may prevent the "cytokine storm&quo . . .
Montefiore Health System and Albert Einstein College of Medicine are the first sites in the nation to begin evaluating an investigational drug in two separate, FDA-approved trials: one to treat mild-to-moderate cases of COVID-19 and the other to treat severely ill COVID-19 patients. They are hopeful that the drug, leronlimab, may prevent the "cytokine storm&quo . . .